Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final FDA Waiver Guidance For Point-Of-Care Diagnostics Unduly Burdensome, Industry Org. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Long-awaited FDA guidance for point-of-care diagnostics to be used in less-sophisticated settings offers leeway in clinical trial design but not enough for industry.

You may also be interested in...



The New Diagnostics Companies

A small number of start-ups are developing novel specilalty-focused diagnostics that capture drug-like revenues and margins without taking drug-like development and regulatory risks. Questions about the business model abound, since most companies need multiple tests to reach profitability and a changing regulatory climate may force these companies to seek FDA approval for their tests, dramatically increasing development risk and cost.

Industry Involvement In Guidance Development Encouraged By FDA Working Group

In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.

Industry Involvement In Guidance Development Encouraged By FDA Working Group

In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.

Topics

UsernamePublicRestriction

Register

PS067356

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel